

2-(3,5-Dimethyl-[1,2,4]triazol-1-yl)-1-((R)-4-[4-(4-fluoro-1H-benzimidazol-2-yl)-2-trifluoromethyl-thiazol-5-yl]-2-methyl-piperazin-1-yl)-ethanone;

1-((R)-4-[4-(4,5-Difluoro-1H-benzimidazol-2-yl)-2-trifluoromethyl-thiazol-5-yl]-2-methyl-piperazin-1-yl)-2-(3,5-dimethyl-[1,2,4]triazol-1-yl)-ethanone; and

5 2-(3,5-Dimethyl-[1,2,4]triazol-1-yl)-1-((R)-2-methyl-4-[2-trifluoromethyl-4-(4-trifluoromethyl-1H-benzimidazol-2-yl)-thiazol-5-yl]-piperazin-1-yl)-ethanone;

or a salt of such a compound.

13. A pharmaceutical composition comprising, as active principle, a compound of Formula
10 (I) according to claim 1 or 12; or a pharmaceutically acceptable salt thereof, and at least one therapeutically inert excipient.

14. A compound according to claim 1 or 12, or a pharmaceutically acceptable salt thereof, for use as a medicament.

15. A compound according to claim 1 or 12, or a pharmaceutically acceptable salt thereof, for use in the prevention or treatment of a disease selected from the group consisting of autoimmune disorders, inflammatory diseases, infectious diseases, transplant rejection, fibrosis, neurodegenerative disorders and cancer.

16. Use of Aa compound according to claim 1 or 12, or a pharmaceutically acceptable salt thereof, ~~for use~~ in the preparation of a medicament for the prevention or treatment of a disease selected from the group consisting of autoimmune disorders, inflammatory
20 diseases, infectious diseases, transplant rejection, fibrosis, neurodegenerative disorders and cancer.